Nuvation Bio (NUVB) Competitors $2.62 +0.31 (+13.15%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVB vs. HCM, APLS, MOR, KYMR, RARE, IMVT, ALVO, CRNX, MIRM, and CPRXShould you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include HUTCHMED (HCM), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Alvotech (ALVO), Crinetics Pharmaceuticals (CRNX), Mirum Pharmaceuticals (MIRM), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Nuvation Bio vs. Its Competitors HUTCHMED Apellis Pharmaceuticals MorphoSys Kymera Therapeutics Ultragenyx Pharmaceutical Immunovant Alvotech Crinetics Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals HUTCHMED (NASDAQ:HCM) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk. Do insiders and institutionals hold more shares of HCM or NUVB? 8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 29.9% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is HCM or NUVB more profitable? HUTCHMED has a net margin of 0.00% compared to Nuvation Bio's net margin of -1,413.43%. HUTCHMED's return on equity of 0.00% beat Nuvation Bio's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Nuvation Bio -1,413.43%-46.14%-36.04% Which has higher valuation & earnings, HCM or NUVB? HUTCHMED has higher revenue and earnings than Nuvation Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$602.20M4.65$37.73MN/AN/ANuvation Bio$7.87M112.97-$567.94M-$0.63-4.15 Does the media prefer HCM or NUVB? In the previous week, Nuvation Bio had 4 more articles in the media than HUTCHMED. MarketBeat recorded 12 mentions for Nuvation Bio and 8 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.36 beat Nuvation Bio's score of 0.27 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 1 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more volatility & risk, HCM or NUVB? HUTCHMED has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Nuvation Bio has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Do analysts recommend HCM or NUVB? HUTCHMED currently has a consensus target price of $28.00, suggesting a potential upside of 74.40%. Nuvation Bio has a consensus target price of $7.33, suggesting a potential upside of 180.65%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryNuvation Bio beats HUTCHMED on 9 of the 15 factors compared between the two stocks. Get Nuvation Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVB vs. The Competition Export to ExcelMetricNuvation BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$882.98M$3.08B$5.62B$20.90BDividend YieldN/A2.29%4.64%3.65%P/E Ratio-4.1220.5030.1628.77Price / Sales112.97363.33463.1459.67Price / CashN/A40.7837.7222.93Price / Book2.387.698.455.44Net Income-$567.94M-$54.75M$3.26B$994.60M7 Day Performance11.33%3.51%3.20%2.49%1 Month Performance18.77%11.04%5.63%1.46%1 Year Performance-4.98%12.94%42.63%15.82% Nuvation Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVBNuvation Bio1.9751 of 5 stars$2.63+13.1%$7.33+179.4%-17.7%$896.59M$7.87M-4.1860Earnings ReportHCMHUTCHMED3.1653 of 5 stars$17.28+0.1%$28.00+62.0%-24.4%$3.01B$630.20M0.001,811Positive NewsAPLSApellis Pharmaceuticals4.6595 of 5 stars$24.26+5.7%$36.83+51.8%-33.9%$2.90B$781.37M-13.33770MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsKYMRKymera Therapeutics3.0833 of 5 stars$43.66+1.6%$59.11+35.4%-6.2%$2.80B$47.07M0.00170News CoverageEarnings ReportAnalyst RevisionRAREUltragenyx Pharmaceutical4.4287 of 5 stars$28.46+0.1%$83.08+191.9%-44.8%$2.69B$560.23M0.001,294Analyst RevisionIMVTImmunovant2.2557 of 5 stars$16.09+2.4%$36.40+126.2%-48.7%$2.69BN/A0.00120Trending NewsEarnings ReportAnalyst ForecastALVOAlvotech3.726 of 5 stars$8.87+0.9%$14.00+57.8%-20.6%$2.65B$491.98M15.151,032CRNXCrinetics Pharmaceuticals3.3951 of 5 stars$28.22+1.4%$69.50+146.3%-42.5%$2.61B$1.04M0.00210Earnings ReportAnalyst ForecastMIRMMirum Pharmaceuticals4.0097 of 5 stars$52.24+0.4%$65.50+25.4%+44.7%$2.58B$336.89M0.00140Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionCPRXCatalyst Pharmaceuticals4.885 of 5 stars$21.73+2.9%$32.83+51.1%+5.4%$2.58B$491.73M13.8480 Related Companies and Tools Related Companies HUTCHMED Alternatives Apellis Pharmaceuticals Alternatives MorphoSys Alternatives Kymera Therapeutics Alternatives Ultragenyx Pharmaceutical Alternatives Immunovant Alternatives Alvotech Alternatives Crinetics Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Catalyst Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NUVB) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvation Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access